Human Papillomavirus (HPV) Vaccine Impact Monitoring Project
To monitor the impact of HPV vaccine on cervical cancer precursors and HPV types associated with those precursors.
Goals and Objectives
- Describe the incidence of HPV-associated CIN 2/3 and AIS and monitor trends over time.
- Obtain diagnostic biopsy specimens on all reported cases of CIN2, CIN 2/3, CIN3 and AIS in females 18 to 39 years of age in Monroe County.
- Obtain additional detailed information on all reported cases of CIN2, CIN 2/3, CIN3 and AIS in females 18 to 39 years of age in Monroe County, including HPV vaccination history, complete demographic information and relevant medical history.
- Describe cervical cancer screening utilization among females 18 to 39 years to monitor trends over time using methodology other than self-report.
The pathology laboratories in our catchment area have been participating in this project for the past four years, and we continue to identify all cases of CIN 2/3 and AIS in women 18 years of age and older. Lists are generated at each lab every month, using anatomic site language to capture all possible cases. Using a combination of administrative data and medical records, complete case information is collected. This includes: patient demographics, health insurance information, ordering provider and submitting pathologist contact information, cervical pathology information related to the current diagnosis, and detailed information relevant to women aged 18-39 years as outlined above.
A randomized sample of women aged 18 to 39 have a cervical pathology specimen selected for highest grade associated with that infection by the designated lab pathologist, retrieved, prepared and submitted to the CDC for histopathologic review and HPV typing.
Case report forms are completed, all data is entered in the common CDC database, and transmitted to the CDC on a monthly basis.
- Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Markowitz LE; HPV-IMPACT Working Group. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes and Control 2012: Feb 23(2):281-288.
Contact the Communicable Disease Surveillance and Prevention program at (585) 224-3075 or by email at Center for Community Health.